Udvalget fandt det ligeledes betænkeligt, at der ikke forelå tilstrækkelige oplysninger om stabiliteten af det aktive stof og af det lægemiddel, der skulle markedsføres.
They also had concerns that there was not enough data on the stability of the active substance and of the medicine that was going to be marketed.